Innovative Diagnostic Tool Minomic's flagship product, MiCheck Prostate, offers a highly accurate blood test for prostate cancer with a sensitivity of 95% and improved specificity, making it a compelling solution for healthcare providers seeking advanced diagnostic options.

Global Commercial Reach The company markets its test in the US through a CLIA-certified lab in Maryland and in Australia via Sonic Healthcare, providing a foundation for further geographic expansion into new territories.

Strong Market Differentiation MiCheck Prostate surpasses traditional PSA testing by reducing false positives and unnecessary biopsies, positioning Minomic as a differentiated player in the prostate cancer diagnostics industry.

Strategic Collaborations Recent partnerships with the NSW Government and publication of supportive research enhance Minomic's credibility and open opportunities for collaborations with health authorities and research institutions.

Growth Potential With annual revenues between $1M and $10M and a small but focused team, Minomic is poised for targeted sales growth, especially as it plans to re-launch and expand its test in additional markets.